title: Past, present, and future challenges in breast cancer treatment.
authors.affiliation: Stanford University School of Medicine, Stanford, CA gsledge@stanford.edu.
authors.forename: George W
authors.initials: GW
authors.lastname: Sledge
authors.affiliation: University of Florida Health Cancer Center, Orlando, FL.
authors.forename: Eleftherios P
authors.initials: EP
authors.lastname: Mamounas
authors.affiliation: MD Anderson Cancer Center, Houston, TX.
authors.forename: Gabriel N
authors.initials: GN
authors.lastname: Hortobagyi
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
authors.affiliation: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, and.
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Goodwin
authors.affiliation: Johns Hopkins Cancer Center, Baltimore, MD.
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Wolff
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000517:prevention & control / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D020869:Gene Expression Profiling; D005820:Genetic Testing; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods; D008408:Mastectomy / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D020360:Neoadjuvant Therapy / Q000379:methods*; D011322:Primary Prevention / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D040242:Risk Reduction Behavior; D021701:Sentinel Lymph Node Biopsy; D064726:Triple Negative Breast Neoplasms / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human